Illumina (NASDAQ:ILMN) Director Scott Gottlieb Purchases 200 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Scott Gottlieb bought 200 shares of the business’s stock in a transaction on Monday, February 9th. The shares were acquired at an average cost of $117.81 per share, with a total value of $23,562.00. Following the purchase, the director owned 12,723 shares of the company’s stock, valued at $1,498,896.63. The trade was a 1.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Illumina Stock Down 2.5%

Shares of ILMN opened at $116.38 on Thursday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a market cap of $17.78 billion, a P/E ratio of 21.35, a price-to-earnings-growth ratio of 2.28 and a beta of 1.45. The company’s 50-day moving average price is $137.81 and its 200 day moving average price is $116.48. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the business posted $0.95 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ILMN. Evercore ISI set a $150.00 price objective on shares of Illumina in a report on Friday, February 6th. Robert W. Baird set a $137.00 price objective on Illumina in a research note on Friday, February 6th. Piper Sandler lowered their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. lowered their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $129.17.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ILMN. Elyxium Wealth LLC acquired a new position in Illumina in the fourth quarter valued at $25,000. Creative Capital Management Investments LLC boosted its position in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. Board of the Pension Protection Fund acquired a new position in Illumina during the fourth quarter worth approximately $26,000. TD Waterhouse Canada Inc. purchased a new stake in Illumina in the fourth quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.